These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 14616878)

  • 1. Effects of treatment with Sandostatin LAR on small dense LDL and remnant-like lipoproteins in patients with acromegaly.
    Tan KC; Pang RW; Tiu SC; Lam KS
    Clin Endocrinol (Oxf); 2003 Nov; 59(5):558-64. PubMed ID: 14616878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sandostatin LAR in acromegaly: a 6-week injection interval suppresses GH secretion as effectively as a 4-week interval.
    Biermasz NR; van den Oever NC; Frölich M; Arias AM; Smit JW; Romijn JA; Roelfsema F
    Clin Endocrinol (Oxf); 2003 Mar; 58(3):288-95. PubMed ID: 12608933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Sandostatin LAR (long-acting somatostatin analogue) is similar in patients with untreated acromegaly and in those previously treated with surgery and/or radiotherapy.
    Ayuk J; Stewart SE; Stewart PM; Sheppard MC;
    Clin Endocrinol (Oxf); 2004 Mar; 60(3):375-81. PubMed ID: 15009004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly.
    Colao A; Marzullo P; Ferone D; Spinelli L; Cuocolo A; Bonaduce D; Salvatore M; Boerlin V; Lancranjan I; Lombardi G
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3132-40. PubMed ID: 10999798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and biochemical response following withdrawal of a long-acting, depot injection form of octreotide (Sandostatin-LAR).
    Stewart PM; Stewart SE; Clark PM; Sheppard MC
    Clin Endocrinol (Oxf); 1999 Mar; 50(3):295-9. PubMed ID: 10435053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison between octreotide-LAR and lanreotide-SR in the chronic treatment of acromegaly.
    Cozzi R; Dallabonzana D; Attanasio R; Barausse M; Oppizzi G
    Eur J Endocrinol; 1999 Sep; 141(3):267-71. PubMed ID: 10474124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of monthly intramuscular injections of Sandostatin LAR with multiple subcutaneous injections of octreotide in the treatment of acromegaly; effects on growth hormone and other markers of growth hormone secretion.
    Hunter SJ; Shaw JA; Lee KO; Wood PJ; Atkinson AB; Bevan JS
    Clin Endocrinol (Oxf); 1999 Feb; 50(2):245-51. PubMed ID: 10396369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Doxazosin reduces prevalence of small dense low density lipoprotein and remnant-like particle cholesterol levels in nondiabetic and diabetic hypertensive patients.
    Hirano T; Yoshino G; Kashiwazaki K; Adachi M
    Am J Hypertens; 2001 Sep; 14(9 Pt 1):908-13. PubMed ID: 11587157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LDL subfractions in acromegaly: relation to growth hormone and insulin-like growth factor-I.
    Tan KC; Shiu SW; Janus ED; Lam KS
    Atherosclerosis; 1997 Feb; 129(1):59-65. PubMed ID: 9069518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Lowered ghrelin levels in acromegaly—normalization after treatment].
    Kozakowski J; Rabijewski M; Zgliczyński W
    Endokrynol Pol; 2005; 56(6):862-70. PubMed ID: 16821203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly.
    Chanson P; Boerlin V; Ajzenberg C; Bachelot Y; Benito P; Bringer J; Caron P; Charbonnel B; Cortet C; Delemer B; Escobar-Jiménez F; Foubert L; Gaztambide S; Jockenhoevel F; Kuhn JM; Leclere J; Lorcy Y; Perlemuter L; Prestele H; Roger P; Rohmer V; Santen R; Sassolas G; Scherbaum WA; Schopohl J; Torres E; Varela C; Villamil F; Webb SM
    Clin Endocrinol (Oxf); 2000 Nov; 53(5):577-86. PubMed ID: 11106918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LDL physical properties, lipoprotein and Lp(a) levels in acromegalic patients. Effects of octreotide therapy. Italian Multicenter Octreotide Study Group.
    Arosio M; Sartore G; Rossi CM; Casati G; Faglia G; Manzato E
    Atherosclerosis; 2000 Aug; 151(2):551-7. PubMed ID: 10924734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of two different somatostatin analogs on glucose tolerance in acromegaly.
    Ronchi C; Epaminonda P; Cappiello V; Beck-Peccoz P; Arosio M
    J Endocrinol Invest; 2002 Jun; 25(6):502-7. PubMed ID: 12109620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum lipoprotein changes following IGF-I normalization using a growth hormone receptor antagonist in acromegaly.
    Parkinson C; Drake WM; Wieringa G; Yates AP; Besser GM; Trainer PJ
    Clin Endocrinol (Oxf); 2002 Mar; 56(3):303-11. PubMed ID: 11940041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin LAR in acromegaly.
    de Herder WW; Taal HR; Uitterlinden P; Feelders RA; Janssen JA; van der Lely AJ
    Eur J Endocrinol; 2005 Jul; 153(1):67-71. PubMed ID: 15994747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of insulin-dependent diabetes on plasma lipoproteins in diabetic pregnancy.
    Knopp RH; Van Allen MI; McNeely M; Walden CE; Plovie B; Shiota K; Brown Z
    J Reprod Med; 1993 Sep; 38(9):703-10. PubMed ID: 8254593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly.
    Davies PH; Stewart SE; Lancranjan L; Sheppard MC; Stewart PM
    Clin Endocrinol (Oxf); 1998 Mar; 48(3):311-6. PubMed ID: 9578821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sandostatin LAR in acromegalic patients: long-term treatment.
    Fløgstad AK; Halse J; Bakke S; Lancranjan I; Marbach P; Bruns C; Jervell J
    J Clin Endocrinol Metab; 1997 Jan; 82(1):23-8. PubMed ID: 8989226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The atherogenic plasma remnant-like particle cholesterol concentration is increased in the fasting and postprandial state in active acromegalic patients.
    Twickler TB; Dallinga-Thie GM; Zelissen PM; Koppeschaar HP; Erkelens DW
    Clin Endocrinol (Oxf); 2001 Jul; 55(1):69-75. PubMed ID: 11453954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Octreotide long-acting release (LAR): a review of its use in the management of acromegaly.
    McKeage K; Cheer S; Wagstaff AJ
    Drugs; 2003; 63(22):2473-99. PubMed ID: 14609359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.